Sponsor or institution
Clinical trials and research at Sun Yat-sen University
As of November 12, 2026, Find a Trial lists 344 clinical trials run by Sun Yat-sen University that are recruiting, at sites in 3 countries (most in China (344), Singapore (1), United States (1)). 3 were first registered in the last 30 days. By phase: Phase 2 (137), Phase 3 (82), Phase 1/2 (10), Phase 1 (9). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 344Clinical trials
- 3New in 30 days
- 3Countries
Newest trials
All recruiting trials (newest 150 of 344)
-
Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer
This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.
-
AI-assisted imaging for diagnosing and managing focal liver lesions
Researchers are testing whether AI-powered imaging can help doctors better diagnose focal liver lesions in adults undergoing CT scans.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Anlotinib Plus PD-1 Inhibitor vs PD-1 Inhibitor Alone After Chemoimmunotherapy in Advanced ESCC
This trial tests whether adding anlotinib to PD-1 inhibitor maintenance after initial chemoimmunotherapy helps people with advanced esophageal squamous cell carcinoma live longer without the cancer growing.
-
Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases
This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.
-
HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma
This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.
-
Triple-drug neoadjuvant therapy for EGFR-positive locally advanced head and neck cancer
This trial tests a three-drug neoadjuvant regimen (Becotatug Vedotin, Pucotenlimab, and Cisplatin) in adults with EGFR-positive, locally advanced head and neck cancer to see if it can shrink tumors before surgery or chemoradiotherapy.
-
Ivosidenib plus intensive chemotherapy for BRAF V600E-mutant colorectal cancer after resistance
This trial tests whether adding ivonescimab to mFOLFOXIRI and celecoxib can help people with BRAF V600E-mutant colorectal cancer who have run out of effective previous treatments.
-
Nanocrystalline Megestrol Acetate to Help Appetite During Chemoradiotherapy in Nasopharyngeal Carcinoma
This phase 3 trial tests whether taking nanocrystalline megestrol acetate can help people with nasopharyngeal carcinoma who are receiving chemoradiotherapy to keep their appetite and weight better than placebo.
-
See if ctDNA MRD testing can guide how long to keep immunotherapy in metastatic MSI-H/dMMR colorectal cancer
This study tests whether plasma ctDNA–based MRD testing can help decide when patients with metastatic MSI-H/dMMR colorectal cancer can safely stop immunotherapy after one year.
-
Neoadjuvant CTLA-4 and PD-1 blockade with chemoradiotherapy for locally advanced ESCC
This trial tests whether giving two immune checkpoint inhibitors before surgery, together with chemoradiotherapy, helps patients with resectable locally advanced esophageal squamous cell carcinoma.
-
Combo of tunlametinib, pucotenlimab, and hydroxychloroquine in NRAS-mutant melanoma
This study tests whether adding hydroxychloroquine to tunlametinib and pucotenlimab helps people with NRAS-mutant melanoma.
-
Culmerciclib with anti-HER2 therapy and endocrine therapy as maintenance in HR+/HER2+ advanced breast cancer
This phase II study tests whether taking culmerciclib with anti-HER2 therapy and hormone-blocking treatment can help people with HR-positive, HER2-positive advanced breast cancer after initial therapy.
-
Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer
This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.
-
Becotatug Vedotin plus Anti-PD-1 as maintenance for recurrent/metastatic NPC
This phase 3 trial tests whether adding becotatug vedotin to an anti-PD-1 therapy as maintenance can help people with recurrent or metastatic nasopharyngeal cancer who have stable disease after initial treatment.
-
Personalized target volume approach for nasopharyngeal cancer radiotherapy
This trial tests whether delineating the primary clinical target volume using a margin-expansion method works as well as the standard guideline-based method in newly diagnosed non-metastatic nasopharyngeal cancer.
-
Transanal vs Robotic Total Mesorectal Excision for Low Rectal Cancer
This study tests whether taTME or robot-assisted TME works better for low rectal cancer patients and whether one method leads to fewer complications or conversions.
-
Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma
This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.
-
Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer
This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.
-
Thymosin Alpha-1 plus PD-1 therapy in older adults with advanced melanoma
This trial tests whether adding Thymosin Alpha-1 to a PD-1 antibody helps people age 60 and up with advanced melanoma.
-
Adebrelimab plus chemotherapy before surgery for borderline-resectable esophageal squamous cell carcinoma
This trial tests whether adding adebrelimab to chemotherapy given before surgery can shrink borderline-resectable ESCC enough to allow curative tumor removal.
-
Neoadjuvant radiotherapy with NALIRIFOX and Adebrelimab in locally advanced rectal cancer
This trial tests whether adding radiotherapy and a PD-1 blocker called Adebrelimab to a chemotherapy regimen (NALIRIFOX) before surgery helps people with locally advanced, pMMR/MSS rectal cancer.
-
Dalpiciclib with Anti-HER2 and Endocrine Therapy as Maintenance in HR+/HER2+ Metastatic Breast Cancer
A phase II trial tests whether adding dalpiciclib to anti-HER2 therapy and endocrine therapy can help advanced HR+/HER2+ breast cancer stay under control after initial treatment.
-
Hypofractionated chemoradiotherapy with tislelizumab and surufatinib for unresectable stage III NSCLC
This phase 2 trial tests whether adding tislelizumab and surufatinib to hypofractionated chemoradiotherapy helps patients with unresectable stage III NSCLC, compared to tislelizumab alone after radiotherapy.
-
Cryoablation plus anti-PD-1 therapy for advanced soft tissue sarcoma
This study tests whether freezing tumors and giving camrelizumab can help people with advanced soft tissue sarcoma after standard treatments have failed.
-
Optimal tunneling method for PICC placement
This study tests whether a one-needle or two-needle tunneling technique is safer and more effective for first-time tunneled PICC catheter placements in adults.
-
HAIC vs. TACE plus sintilimab and bevacizumab for intermediate HCC with high tumor burden
This trial tests whether FOLFOX-HAIC plus immunotherapy and anti-angiogenic therapy works better than TACE plus the same systemic therapy for adults with intermediate-stage hepatocellular carcinoma with tumors beyond Up-To-Seven criteria.
-
Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors
This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.
-
Teniposide + cisplatin + serplulimab versus etoposide + cisplatin + serplulimab for extensive-stage small-cell lung cancer
This study tests whether replacing etoposide with teniposide, while keeping cisplatin and serplulimab, works better for adults with extensive-stage small-cell lung cancer.
-
Sintilimab plus anlotinib and a taxane for recurrent or metastatic nasopharyngeal carcinoma
This trial will test whether adding the PD‑1 drug sintilimab and the oral anti‑angiogenic anlotinib to a taxane chemotherapy helps adults with recurrent or metastatic nasopharyngeal carcinoma who have already failed platinum chemotherapy and/or prior anti‑PD‑1/PD‑L1 therapy.
-
Taurine to help prevent and treat mouth ulcers from radiation in NPC
This study tests whether taurine can help prevent and lessen severe radiation-induced oral mucositis in adults with newly diagnosed nasopharyngeal carcinoma receiving radiotherapy.
-
Megestrol Acetate to Help Fatigue in T-DXd-Treated Breast Cancer
This study tests whether adding Megestrol Acetate at the start of Trastuzumab Deruxtecan therapy can reduce fatigue and improve quality of life for adults with advanced HER2-positive breast cancer.
-
Antegrade intestinal fluid reinfusion to prevent low anterior resection syndrome in rectal cancer patients with ileostomy
This trial will test whether putting a patient's intestinal fluid back through their ileostomy before it is closed can prevent low anterior resection syndrome in people treated for mid to low rectal cancer.
-
Iparomlimab and Tuvonralimab with albumin‑bound paclitaxel and lenvatinib for second‑line advanced biliary tract cancer
This trial tests whether adding two immune antibodies (Iparomlimab and Tuvonralimab) to paclitaxel and lenvatinib can help people with unresectable or metastatic biliary tract cancer whose disease progressed after one prior platinum‑based or gemcitabine-containing regimen.
-
Neoadjuvant CAPOX chemotherapy with or without pucotenlimab plus selective short-course radiotherapy for locally advanced rectal cancer
This trial tests whether adding the immunotherapy drug pucotenlimab to CAPOX chemotherapy, with selective short-course radiotherapy if needed, helps people with pMMR/MSS locally advanced rectal cancer shrink their tumors before surgery.
-
Maintenance immunotherapy with deferred salvage radiotherapy after response to chemoimmunotherapy in recurrent nasopharyngeal cancer
This study tests whether continuing immunotherapy and delaying salvage radiotherapy after an initial chemoimmunotherapy response can help people with unresectable recurrent nasopharyngeal cancer live longer and feel better.
-
Becotatug vedotin plus PD-1 inhibitor versus PD-1 inhibitor alone for EGFR‑positive resectable locally advanced head and neck cancer
This trial will test if adding becotatug vedotin to a PD‑1 blocker given before and after surgery helps people with EGFR‑positive, CPS≥1 resectable locally advanced head and neck cancer do better than a PD‑1 blocker alone.
-
Eribulin plus anlotinib for HER2‑negative recurrent or metastatic breast cancer after ADCs
This trial tests whether combining eribulin and anlotinib helps people with HER2‑negative recurrent or metastatic breast cancer whose disease progressed after antibody‑drug conjugates.
-
Chidamide, sintilimab and bevacizumab as second-line treatment for advanced extrapulmonary neuroendocrine carcinoma
This trial tests whether the combination of chidamide, sintilimab, and bevacizumab can shrink tumors in adults with advanced extrapulmonary neuroendocrine carcinoma who progressed after first-line therapy.
-
Tracking tumor DNA over time in neuroblastoma
This project tests whether regular blood tests measuring circulating tumor DNA and molecular residual disease can track disease status and detect relapse earlier in children with neuroblastoma.
-
Flushing the rectum during laparoscopic surgery to lower the chance of cancer coming back after mid-to-low rectal cancer removal
This will test whether flushing the rectum during laparoscopic removal of mid-to-low rectal cancer lowers the chance the cancer comes back near the original site.
-
Darolutamide with ADT and Low-Dose Docetaxel in Advanced Prostate Cancer
This trial tests whether adding a low dose of docetaxel to darolutamide plus androgen deprivation therapy helps patients with metastatic hormone-sensitive prostate cancer achieve undetectable PSA levels.
-
Intensified versus conversion therapy for advanced liver cancer after first-line bevacizumab plus sintilimab fails
This study tests whether adding lenvatinib or switching to regorafenib plus a PD-1 blocker works better and is safe for adults with advanced hepatocellular carcinoma whose cancer progressed after first-line bevacizumab plus sintilimab.
-
Becotatug vedotin added to radiation and adjuvant therapy for locally advanced nasopharyngeal cancer with a poor response to induction chemo‑immunotherapy
This will test whether adding becotatug vedotin during radiation and afterward helps people with locally advanced nasopharyngeal cancer who had a suboptimal response to induction chemotherapy combined with immunotherapy.
-
Celecoxib Plus R-CHOP vs R-CHOP in newly diagnosed CD5-positive DLBCL
This study tests whether adding celecoxib to standard R-CHOP therapy helps people with newly diagnosed CD5-positive DLBCL see more complete responses.
-
TACE or Ablation With Sintilimab and Ipilimumab Before Surgery for Liver Cancer
This study tests whether combining local tumor treatments with immunotherapy before surgery helps people with resectable hepatocellular carcinoma at higher risk of recurrence.
-
SBRT combined with becotatug vedotin for EGFR‑positive oligometastatic cancer
This trial will try combining focused radiation (SBRT) with the antibody‑drug conjugate becotatug vedotin plus standard systemic therapy for adults with EGFR‑positive oligometastatic solid tumors to see if it improves disease control and survival.
-
Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain
This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.
-
Causes and outcomes of coronary artery disease over time
We will follow adults with coronary artery disease to see if certain risk factors are linked to dying from any cause or from heart-related causes.
-
Radiotherapy after prostate removal for node-positive prostate cancer
This study tests whether adding pelvic radiotherapy to ongoing hormone therapy helps men with node-positive prostate cancer after prostate removal live longer without cancer progression.
-
4-Week Online Parenting Program to Support Healthy Habits in Preschoolers
This 4-week online program tests whether teaching parents motivation, planning, and habit strategies helps them better support healthy behaviors in their preschool children (ages 3–6).
-
AI teaching assistant for a graduate medical machine learning course
This project will test whether an AI teaching assistant helps medical and nursing graduate students in a Machine Learning and Data Mining course improve their grades, coding skills, and confidence.
-
Low-dose radiotherapy with pucotenlimab and CAPEOX for pMMR locally advanced rectal cancer
This trial will try adding a single low dose of radiotherapy to the immunotherapy drug pucotenlimab plus CAPEOX chemotherapy before surgery to see if it improves tumor response in people with pMMR/MSS locally advanced rectal cancer.
-
Intraperitoneal liposomal irinotecan alone or with rmhTNF or bevacizumab for malignant ascites after prior treatments
This will try an injected form of liposomal irinotecan, alone or with rmhTNF or bevacizumab, in adults with malignant ascites who have not responded to standard therapies.
-
Immunotherapy versus capecitabine maintenance after chemo‑chemoradiotherapy for high‑risk nasopharyngeal cancer
This test compares PD‑1 immunotherapy maintenance to capecitabine maintenance after chemo‑chemoradiotherapy for people with high‑risk locally advanced nasopharyngeal cancer who responded to initial chemo‑immunotherapy.
-
Iparomlimab and Tuvonralimab plus lenvatinib before kidney-sparing surgery for clear cell kidney cancer
This will test whether giving Iparomlimab and Tuvonralimab (QL1706) together with lenvatinib before surgery helps people with localized clear cell kidney cancer (T1–T2) who need but may have difficulty getting kidney-preserving surgery because of a high R.E.N.A.L. score.
-
Pucotenlimab plus vorolanib before surgery for clear cell kidney cancer
This trial tests whether giving pucotenlimab with vorolanib before surgery can shrink localized clear cell kidney tumors and make kidney-sparing surgery easier for adults with difficult-to-remove tumors.
-
QL1706 with lenvatinib for previously treated penile cancer
This trial tests whether combining QL1706 with lenvatinib can help control advanced or metastatic penile squamous cell carcinoma in people whose disease progressed after prior treatments.
-
SBRT vs surgical removal for small liver cancer (HCC)
This study tests whether stereotactic body radiotherapy (SBRT) can be as effective as surgical removal for small hepatocellular carcinoma in adults who are eligible for either option.
-
Fasting-mimicking diet plus chemo‑immunotherapy for early or locally advanced triple‑negative breast cancer
We will try adding a fasting-mimicking diet to standard pre-surgery chemotherapy and immunotherapy (toripalimab) in women with early-stage or locally advanced triple-negative breast cancer to see if it improves tumor response and is safe.
-
Magnetic tracking and ECG-guided tip confirmation for PICC placement
This project tests whether a magnetic tracking tip confirmation system (Sherlock 3CG) leads to more accurate and faster PICC tip placement than traditional ECG-guided positioning in cancer patients at high risk for PICC-related thrombosis.
-
Toripalimab with three platinum-based induction chemotherapies for locally advanced nasopharyngeal carcinoma
This trial tests whether adding toripalimab to one of three different platinum-based induction chemotherapy regimens before standard concurrent chemoradiotherapy can improve outcomes for adults with locally advanced nasopharyngeal carcinoma.
-
Selective completion total mesorectal excision guided by intra-operative frozen pathology after local excision for low rectal cancer
This trial tests whether using an immediate frozen-pathology result after local excision to decide if a full total mesorectal excision is needed can keep cancer controlled for adults with low rectal cancer who had a near-complete or small residual response to preoperative chemoradiotherapy.
-
Neoadjuvant paclitaxel polymersomes with carboplatin and adebrelimab for resectable mucosal melanoma
This trial tests whether giving paclitaxel polymersomes together with carboplatin and adebrelimab before surgery helps people with resectable mucosal melanoma.
-
PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation for locally advanced recurrent nasopharyngeal carcinoma
This phase II trial tests whether immediate or selective re-irradiation after a good response to PD-1 inhibitor plus gemcitabine-cisplatin helps people with locally advanced recurrent nasopharyngeal carcinoma live longer with acceptable side effects.
-
Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer
This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.
-
Lower-dose versus standard-dose radiation with concurrent chemoimmunotherapy for advanced nasopharyngeal cancer after a strong response to induction treatment
This trial tests whether giving lower-dose radiation alongside ongoing chemotherapy and immunotherapy works as well as standard-dose radiation for people with locally advanced nasopharyngeal cancer who had a strong response and undetectable EBV DNA after induction chemoimmunotherapy.
-
Cold ischemia during robot-assisted partial nephrectomy
This trial will test whether using ice around the kidney during robot-assisted partial nephrectomy helps the operated kidney recover function faster in adults with kidney cancer.
-
Low-dose radiotherapy with toripalimab and chemotherapy for recurrent or metastatic nasopharyngeal cancer
This will test whether adding low-dose radiotherapy to toripalimab plus gemcitabine‑cisplatin helps people with recurrent or metastatic nasopharyngeal cancer respond better while staying safe.
-
Sintilimab plus bevacizumab biosimilar before surgery for resectable liver cancer
This trial will test whether giving sintilimab together with a bevacizumab biosimilar before surgery helps people with resectable hepatocellular carcinoma beyond the Milan criteria.
-
Houyanqing oral liquid to prevent and treat radiation mouth sores in nasopharyngeal cancer
This phase 3 trial will test whether adding Houyanqing oral liquid to standard care can prevent or lessen radiation-caused mouth sores in adults receiving radiotherapy for nasopharyngeal cancer.
-
Postoperative Low Oxygen and Chance of Leaks After Esophageal Surgery
This study looks at whether low oxygen levels after esophageal cancer surgery increase the chance of an anastomotic leak.
-
Neoadjuvant SBRT then sintilimab with chemotherapy for N3-positive locally advanced NSCLC
This approach tests whether focused radiation to the primary lung tumor followed by two cycles of sintilimab plus platinum-based chemotherapy before surgery can shrink N3-positive locally advanced non-small cell lung cancer and enable curative surgery.
-
Using blood DNA 5hmC markers and the SCCG chemotherapy protocol to predict response and monitor relapse in children with hepatoblastoma
This trial will test whether a blood-based DNA marker (5hmC) together with the SCCG treatment plan can predict chemotherapy response and detect recurrence in children and adolescents with hepatoblastoma.
-
WTX212A alone or combined with radiotherapy for advanced solid tumors
This study will test whether WTX212A, given alone or together with radiotherapy, can help people with advanced solid tumors.
-
Sac-TMT plus KL-A167 for PD-L1–positive, hormone receptor–positive/HER2–negative metastatic breast cancer after CDK4/6 inhibitors
This treatment combines Sac-TMT and KL-A167 to see if it can control disease in people with PD-L1–positive, HR+/HER2– metastatic breast cancer whose disease progressed after CDK4/6 inhibitors.
-
Trastuzumab Rezetecan with or without Adebrelimab for HER2-expressing advanced urothelial cancer
This study will test whether Trastuzumab Rezetecan alone or combined with the immunotherapy Adebrelimab helps people with HER2-expressing locally advanced or metastatic urothelial cancer.
-
Dalpiciclib plus camrelizumab for advanced liver cancer after prior immunotherapy
This trial will test whether combining dalpiciclib with camrelizumab can control tumors in people with unresectable hepatocellular carcinoma whose cancer progressed after prior immune checkpoint inhibitor treatment.
-
PD-1 immunotherapy with chemotherapy followed by immediate or delayed local radiation for newly metastatic nasopharyngeal cancer
This trial tests whether waiting to give local radiotherapy (only if needed) after PD‑1 immunotherapy plus gemcitabine‑cisplatin works as well and causes less toxicity than giving radiotherapy right away for people with newly diagnosed metastatic nasopharyngeal cancer who respond to initial treatment.
-
Factors that affect how well mesenchymal stromal cell (MSC) therapy works for hepatitis B–related acute-on-chronic liver failure.
This project will look back at people with hepatitis B–related ACLF who received MSC infusions to see which factors affect whether the treatment helps.
-
FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer
This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.
-
Reduced-target versus full-target IMRT after chemo and immunotherapy for metastatic nasopharyngeal cancer
This trial will test whether smaller (reduced-target) radiotherapy after first-line chemo plus immunotherapy works as well as standard full-target radiotherapy for people with newly diagnosed distant metastatic nasopharyngeal cancer who responded to initial treatment.
-
Teniposide plus cisplatin for newly diagnosed central malignant germ cell tumors
This trial tests whether giving teniposide together with cisplatin helps people newly diagnosed with central malignant germ cell tumors.
-
Pucotenlimab with lenvatinib and chemotherapy for children with advanced or relapsed hepatoblastoma
This study will test whether pucotenlimab combined with lenvatinib and irinotecan can help children aged 2–18 whose hepatoblastoma did not respond to prior treatments.
-
Toripalimab plus capecitabine after chemoradiotherapy for esophageal squamous cell carcinoma
This trial will test whether giving toripalimab together with low‑dose capecitabine after definitive chemoradiotherapy helps people with locally advanced esophageal squamous cell carcinoma live longer and have fewer recurrences.
-
Risk prediction for HBV-related liver cancer
This project tests an AI-based follow-up system to try to improve early detection of liver cancer in people with chronic hepatitis B and related risk factors.
-
Adaptive immunotherapy for nasopharyngeal carcinoma
This trial will test whether, after induction chemoimmunotherapy, low‑risk patients with undetectable EBV‑DNA can be safely treated with radiotherapy alone instead of concurrent chemoradiotherapy, and whether adding capecitabine to adjuvant immunotherapy improves outcomes for high‑risk patients with detectable EBV‑DNA
-
IB-FOLFIRI for BRAF V600E metastatic colorectal cancer
This trial tests whether adding the immune drugs Iparomlimab and Tuvonralimab to bevacizumab and FOLFIRI helps adults with BRAF V600E metastatic colorectal cancer.
-
Postoperative cisplatin with radiation versus radiation alone for intermediate‑risk head and neck squamous cell carcinoma
This test sees if adding cisplatin chemotherapy to radiation after surgery helps people with intermediate‑risk head and neck squamous cell carcinoma stay cancer‑free longer and live longer.
-
Neoadjuvant chemotherapy and dual immunotherapy with chemoradiation for unresectable stage III non-small cell lung cancer
This trial will test whether giving two immune checkpoint drugs before and after chemoradiation, along with targeted agents, helps people with unresectable stage III non-small cell lung cancer.
-
Iparomlimab and Tuvonralimab plus nimotuzumab for recurrent or metastatic nasopharyngeal carcinoma after first-line treatment failure
This will try combining two immune-targeting drugs, iparomlimab and tuvonralimab, with the antibody nimotuzumab to see if it helps people with recurrent or metastatic nasopharyngeal cancer whose first-line cisplatin-based treatment has failed.
-
Golidocitinib with liposomal mitoxantrone or chidamide for relapsed or refractory peripheral T‑cell lymphoma
This trial tests whether adding golidocitinib to either liposomal mitoxantrone or chidamide helps adults with relapsed or refractory peripheral T‑cell lymphoma.
-
Adaptive chemotherapy for advanced breast cancer after standard treatment
This tests whether tailoring chemotherapy choices (gemcitabine, vinorelbine, eribulin, or utidelone) can improve outcomes for people whose advanced breast cancer has progressed after standard treatments.
-
Surufatinib with chemo-immunotherapy and chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
This trial will test whether adding surufatinib to two cycles of chemo-immunotherapy followed by concurrent chemoradiotherapy helps people with unresectable, locally advanced esophageal squamous cell carcinoma.
-
Concurrent chemoradiotherapy with surufatinib and tislelizumab for unresectable stage III non-small cell lung cancer
This tests whether adding surufatinib and tislelizumab to standard concurrent chemoradiotherapy, followed by continuing both drugs as consolidation, helps people with unresectable stage III non-small cell lung cancer.
-
Xinlikang capsules for chemo-related fatigue and immune problems after DLBCL treatment
This trial will test whether Xinlikang capsules can reduce chemotherapy-related fatigue and improve peripheral blood lymphocyte counts in adults with diffuse large B-cell lymphoma who are in complete remission after first-line chemotherapy.
-
Relmacabtagene autoleucel plus sintilimab for relapsed or refractory CD19‑positive B‑cell lymphoma
This trial will test whether giving relmacabtagene autoleucel followed by the PD‑1 drug sintilimab helps adults with relapsed or refractory CD19‑positive large B‑cell, follicular, or mantle cell lymphoma.
-
Combination therapies for PD-1–resistant recurrent or metastatic nasopharyngeal cancer
This trial will try four different treatment regimens in people with recurrent or metastatic nasopharyngeal cancer who no longer respond to anti‑PD‑1 therapy after prior platinum chemotherapy.
-
How new metabolites affect valvular heart disease
This project will test whether newly identified metabolites influence disease progression and outcomes in adults with valvular heart disease.
-
AK104 plus TACE with surgery for resectable high‑risk liver cancer (real‑world cohort)
This project follows people with resectable, high‑risk hepatocellular carcinoma who have surgery without neoadjuvant AK104 plus TACE to compare their outcomes with patients who received the neoadjuvant approach.
-
Fractionated stereotactic radiotherapy plus bevacizumab for multiple brain metastases from lung adenocarcinoma
This trial tests whether adding bevacizumab to fractionated stereotactic radiotherapy improves intracranial control for people with multiple brain metastases from lung adenocarcinoma.
-
Hypofractionated versus conventional chemoradiotherapy followed by consolidative immunotherapy for locally advanced NSCLC
This trial tests whether a shorter, higher-dose (hypofractionated) chemoradiotherapy course followed by up to 12 months of immunotherapy works as well or better than standard fractionated chemoradiotherapy plus the same immunotherapy for people with unresectable, locally advanced non-small cell lung cancer.
-
Endoscopy versus esophagram to check the anastomosis after McKeown esophagectomy
This comparison tries to see whether endoscopy or esophagram is better for checking the surgical connection about seven days after McKeown esophagectomy in patients treated for esophageal cancer.
-
Real-world cardiometabolic protection outcomes
This project will test whether common cardiometabolic risk factors predict death and major heart-related events in adults with hypertension, diabetes, obesity, dyslipidemia, or high uric acid.
-
Predicting afterload mismatch after transcatheter mitral edge-to-edge repair
It will test a model to predict which adults having transcatheter mitral valve edge-to-edge repair will develop afterload mismatch after the procedure.
-
ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer
This trial tests whether a ctDNA blood test can help choose cetuximab plus trifluridine/tipiracil versus bevacizumab plus trifluridine/tipiracil for people with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after prior treatments.
-
Skipping the clinical target volume (CTV) around the primary tumor in limited-stage small cell lung cancer
This trial tests whether giving chest radiotherapy that skips the usual extra margin around the main tumor is as effective and causes fewer side effects for people with limited-stage small cell lung cancer who have responded to initial chemotherapy.
-
Combining Orelabrutinib and Zuberitamab for treating Marginal Zone Lymphoma
This study is testing if combining two medications, Orelabrutinib and Zuberitamab, can help people with untreated Marginal Zone Lymphoma feel better and have fewer side effects.
-
Personalized immunochemotherapy for lung cancer using ctDNA guidance
This study is testing if using blood tests to check for cancer DNA can help doctors give better and safer treatment cycles to patients with operable non-small cell lung cancer.
-
Evaluating Pucotenlimab for treating pediatric lymphoepithelioma-like carcinoma
This study is testing a new treatment combining pucotenlimab with chemotherapy to see if it helps children and teenagers with a rare type of cancer called lymphoepithelioma-like carcinoma.
-
Using Entecavir to Prevent Hepatitis B Reactivation in Gastrointestinal Cancer Patients
This study is testing whether giving the antiviral drug entecavir early or only when needed can help prevent hepatitis B from getting worse in patients with gastrointestinal cancer who carry the virus.
-
Almonertinib plus palbociclib for advanced KRAS‑mutant solid tumors
We will test whether combining almonertinib with palbociclib is safe and shows early signs of benefit for adults with advanced solid tumors that have KRAS mutations.
-
QL1706 treatment for advanced bone and soft tissue sarcoma
This will try QL1706 in adults with advanced or metastatic bone and soft tissue sarcomas to see if it controls tumor growth and is well tolerated.
-
Study on risk factors and outcomes in patients with tricuspid regurgitation
This study looks at patients with tricuspid regurgitation in the hospital to see what factors affect their health outcomes and how likely they are to face serious issues or death.
-
Almonertinib after one‑lung surgery for suspected cancer nodules in the other lung of EGFR‑mutant NSCLC patients
This test tries whether three months of the EGFR blocker almonertinib can shrink or control suspected cancer nodules in the opposite lung of people with EGFR‑mutant non‑small cell lung cancer who already had one lung removed.
-
Treatment for operable recurrent nasopharyngeal carcinoma
This study is testing a new combination of medications for patients with operable recurrent nasopharyngeal cancer to see if it helps them live longer without the cancer coming back.
-
Comparing reduced dose and standard dose radiotherapy for early stage nasopharyngeal carcinoma
This study is testing if a lower dose of radiotherapy is just as effective as the standard dose for patients with early stage nasopharyngeal carcinoma who have responded well to initial treatment.
-
Comparing two types of chemoradiotherapy for advanced esophageal cancer
This study is testing whether a new way of giving chemotherapy and radiation can help people with advanced esophageal cancer feel better and stay safe compared to the standard method.
-
Combining radiotherapy with immunotherapy and chemotherapy for rectal cancer treatment
This study is testing if a new combination of short-term radiotherapy, immunotherapy, and chemotherapy can help people with locally advanced rectal cancer do better before surgery.
-
Using probiotics with immunotherapy for advanced bladder cancer
This study is testing if adding a probiotics treatment to immunotherapy can help people with advanced bladder cancer do better after previous treatments.
-
Combination of Toripalimab and Celecoxib for Advanced Colorectal Cancer
This study is testing if a combination of two medications, Toripalimab and Celecoxib, can help patients with advanced colorectal cancer avoid surgery and improve their treatment outcomes.
-
Combining bortezomib and cisplatin for advanced breast cancer
This study is testing if combining two cancer drugs, bortezomib and cisplatin, can help women with advanced breast cancer who haven't had success with other treatments.
-
Combining TACE and surgery for large liver tumors
This study is testing if a treatment called TACE before surgery can help people with large liver tumors do better after surgery and have fewer chances of the cancer coming back.
-
Treatment of advanced pancreatic cancer with IX001 TCR-T injection
This study is testing a new treatment called IX001 TCR-T injection for people with advanced pancreatic cancer who have a specific KRAS G12V mutation to see if it is safe and effective.
-
Exploring treatment strategies for HER2-low breast cancer using antibody-drug conjugates
This study looks at how different treatment plans using antibody-drug conjugates can help people with HER2-low breast cancer and what factors might affect their outcomes.
-
Assessing risks and outcomes in patients with mitral regurgitation
This study looks at patients with moderate to severe mitral regurgitation to see what factors might affect their health outcomes and help doctors make better treatment decisions.
-
Optimizing screening methods for nasopharyngeal carcinoma using EBV biomarkers
This study is testing new ways to screen for nasopharyngeal cancer using blood tests for certain virus markers to see if they work better than the current methods for people at high risk.
-
Evaluating Telpegfilgrastim for preventing neutropenia in pediatric cancer patients undergoing chemotherapy
This study is testing if a new drug called Telpegfilgrastim can help prevent low white blood cell counts in teenagers with cancer who are getting strong chemotherapy.
-
Combining Golidocitinib and Pomalidomide for treating relapsed T-cell lymphoma
This study is testing a new combination of two medications, Golidocitinib and Pomalidomide, to see if it can help people with relapsed T-cell lymphoma feel better.
-
Prostate cryoablation plus low-dose cyclophosphamide with hormonal therapy for metastatic prostate cancer
This trial will test whether adding prostate cryoablation and continuous low-dose cyclophosphamide to standard hormone therapy with a modern androgen receptor blocker helps men with newly diagnosed metastatic prostate cancer live longer without PSA progression.
-
Treatment for advanced nasopharyngeal carcinoma using targeted therapy and immunotherapy.
This study is testing a new combination of targeted therapy and immunotherapy with chemotherapy to see if it helps people with advanced nasopharyngeal cancer live longer without their disease getting worse.
-
NK cell therapy using umbilical cord blood for high-risk pediatric soft tissue sarcoma
This study is testing if a new treatment using natural killer cells from umbilical cord blood can help children with high-risk soft tissue sarcoma feel better and improve their chances of recovery.
-
Sintilimab combined with AVD chemotherapy for treating pediatric Hodgkin lymphoma
This study is testing if a new immunotherapy combined with standard chemotherapy can help children and teens with low-to-intermediate risk Hodgkin lymphoma feel better and improve their treatment results.
-
Acalabrutinib with rituximab for untreated mantle cell lymphoma in older adults and lower-risk younger patients
This trial tests whether combining acalabrutinib and rituximab can produce complete remissions at 12 months in people with untreated mantle cell lymphoma who are elderly or younger with low- to intermediate-risk disease.
-
CAR-T cell therapy for relapsed neuroblastoma and desmoplastic small round cell tumors
This study is testing a new CAR-T cell therapy to see if it can help people with relapsed neuroblastoma and desmoplastic small round cell tumors feel better and improve their chances of survival.
-
Stratified treatment for pediatric rhabdomyosarcoma based on risk factors
This study is testing a new treatment plan for children with rhabdomyosarcoma to see if combining chemotherapy and radiotherapy helps improve survival based on their risk levels.
-
AI model predicts distant metastasis in nasopharyngeal cancer
This study is testing a new AI tool to see if it can help doctors predict which patients with nasopharyngeal cancer are at high risk for spreading the disease, so they can get the right scans and avoid unnecessary ones.
-
AI model for diagnosing lymph node metastasis in nasopharyngeal carcinoma
This study is testing a new AI tool that helps doctors diagnose if nasopharyngeal carcinoma has spread to lymph nodes by looking at MRI images before and after chemotherapy.
-
Irinotecan liposome plus temozolomide and fluzoparib for recurrent or metastatic Ewing sarcoma
This will test a combination of liposomal irinotecan, temozolomide, and the PARP inhibitor fluzoparib in adults with recurrent or metastatic Ewing sarcoma after first-line chemotherapy.
-
Combining EGFR antibody, PD-1 inhibitor, and chemotherapy for advanced nasopharyngeal carcinoma
This study tests a new combination of treatments using an EGFR antibody, a PD-1 inhibitor, and chemotherapy to see if it helps people with advanced nasopharyngeal carcinoma feel better compared to standard options.
-
Investigating genetic factors in a rare lung cancer
This study is trying to find out if certain genes are linked to a rare lung cancer that mostly affects people in Asia by comparing the genetic information of patients with the disease to healthy individuals.
-
Combination treatment of sintilimab and linperlisib for relapsed NK/T-cell lymphoma
This study is testing a new combination of two drugs, sintilimab and linperlisib, to see if it can help people with relapsed NK/T-cell lymphoma who haven't had success with other treatments.
-
Collecting data on treatment effectiveness and safety for patients with advanced liver cancer
This study is testing how well a combination of a specific cancer treatment and immunotherapy works for patients with advanced liver cancer who haven't been treated before or have had their cancer come back.
-
NPC Screening Cohort in South China
This study tests a comprehensive screening approach to identify nasopharyngeal carcinoma in adults aged 30-69 who live in NPC-endemic regions by combining EBV tests, questionnaires, and clinical exams.
-
Exploring personalized treatment for recurrent gynecological cancers
This study is testing if using genetic information to guide treatment can help improve outcomes for people with recurrent ovarian, cervical, or endometrial cancer.
-
Using Biolosion with standard therapy to treat triple-negative breast cancer
This study is testing if adding a new oral probiotic called Biolosion to standard treatment can help women with locally advanced triple-negative breast cancer have better outcomes.
-
Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments
This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.
-
Using irinotecan to treat children with relapsed solid tumors based on their UGT1A1 gene
This study is testing if a combination of irinotecan, temozolomide, and vincristine can help children with relapsed solid tumors who have a specific gene type feel better and live longer.
-
Comparing R-CMOP and R-CHOP for treating diffuse large B-cell lymphoma
This study is testing which treatment, R-CMOP or R-CHOP, works better and is safer for adults with low-risk and medium-risk diffuse large B-cell lymphoma.
-
Combination of QL1706 and Chemoradiotherapy for Advanced Nasopharyngeal Cancer
This study is testing if adding a new drug called QL1706 to standard chemotherapy and radiation can help people with advanced nasopharyngeal cancer live better and longer.
Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.
Quick answers
How many clinical trials run by Sun Yat-sen University are recruiting right now?
344, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (344 trials), Singapore (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 137, Phase 3: 82, Phase 1/2: 10, Phase 1: 9. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.